OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030.
Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.
"OZEM offers investors a unique opportunity to efficiently access the companies leading the charge against the global obesity epidemic," said Dave Mazza, CEO of Roundhill Investments. "With obesity rates nearly tripling since 1975 and projected to affect over half the population by 2035, the market for weight loss drugs is in its early stages, offering substantial growth potential for companies pioneering innovation in the space."
The obesity treatment market is set for explosive growth. Goldman Sachs Research forecasts that the market could expand by more than 16 times its current size to reach $100 billion by 2030.2
The Roundhill GLP-1 & Weight Loss ETF (OZEM) is an actively-managed ETF that is designed to provide exposure to a global portfolio of companies involved in developing weight loss therapeutics.
The fund's top holdings include:
HOLDINGS | % WEIGHTING |
Eli Lilly & Co | 20.16 % |
Novo Nordisk A/S | 19.90 % |
Innovent Biologics Inc | 4.59 % |
Zealand Pharma A/S | 4.57 % |
Chugai Pharmaceutical Co Ltd | 4.47 % |
Amgen Inc | 4.24 % |
Altimmune Inc | 4.19 % |
Viking Therapeutics Inc | 3.50 % |
Terns Pharmaceuticals Inc | 3.41 % |
Structure Therapeutics Inc | 3.24 % |
Holdings are subject to change. Data as of 5/20/24.
1 WHO, Global Health Observatory (2022), Ourworldindata.com, 2 Goldman Sachs Global Investment Research; Company data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.